Latest news

• Roche gets wider approval for haemophilia drug Hemlibra

  Roche gets wider approval for haemophilia drug Hemlibra. Approved to treat bleeding episodes in patients without inhibitors. ... Hemlibra (eculizumab) was cleared for use in patients with inhibitors last year, and is now the only FDA-approved drug for

• Bayer roll-out of haemophilia drug Jivi gathers pace

  Meanwhile, the imminent regulatory verdict in the US for Roche’s Hemlibra (emicizumab) in haemophilia A patients without inhibitors to factor VIII, which could dramatically broaden the number of patients eligible

• Roche highlights Hemlibra data as key FDA date approaches

  Roche highlights Hemlibra data as key FDA date approaches. Expanded use would see revenues take off. ... It also says 98% of patients in this trial preferred Hemlibra over factor VIII prophylaxis.

• Immunology keeps Shire figures solid as Takeda takeover nears

  However, Shire’s drugs for haemophilia patients with inhibitors such as Feiba came under competitive pressure from the likes of Roche’s recently-approved Hemlibra (emicizumab), falling 6%.

• NHS England says yes to Roche's Hemlibra

  NHS England says yes to Roche's Hemlibra. But blocks funding for Actelion's Uptravi. ... Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England.